急性呼吸窘迫综合征：近期进展回顾与未来展望
Acute Respiratory Distress Syndrome; A Review of Recent Updates and a Glance into the Future.
作者信息
Ramji Husayn F, Hafiz Maida, Altaq Hiba Hammad, Hussain Syed Talal, Chaudry Fawad
机构信息
University of Oklahoma College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
出版信息
Diagnostics (Basel). 2023 Apr 24;13(9):1528. doi: 10.3390/diagnostics13091528.
Acute respiratory distress syndrome (ARDS) is a rapidly progressive form of respiratory failure that accounts for 10% of admissions to the ICU and is associated with approximately 40% mortality in severe cases. Despite significant mortality and healthcare burden, the mainstay of management remains supportive care. The recent pandemic of SARS-CoV-2 has re-ignited a worldwide interest in exploring the pathophysiology of ARDS, looking for innovative ideas to treat this disease. Recently, many trials have been published utilizing different pharmacotherapy targets; however, the long-term benefits of these agents remain unknown. Metabolomics profiling and stem cell transplantation offer strong enthusiasm and may completely change the outlook of ARDS management in the near future.
急性呼吸窘迫综合征（ARDS）是一种迅速进展的呼吸衰竭形式，占重症监护病房（ICU）入院人数的10%，在严重病例中死亡率约为40%。尽管死亡率高且医疗负担重，但治疗的主要手段仍是支持性治疗。最近的新型冠状病毒肺炎（SARS-CoV-2）大流行重新激发了全球对探索ARDS病理生理学的兴趣，寻找治疗这种疾病的创新方法。最近，许多试验利用不同的药物治疗靶点发表；然而，这些药物的长期益处仍然未知。代谢组学分析和干细胞移植带来了很大希望，可能在不久的将来彻底改变ARDS的治疗前景。
Zotero 插件